(PRX) par generic zegerid

Quote

Anonymous

Guest
par will release zegerid 11-Mar-10 07:46 am as zaks states "DEVASTATING"


PAR BATS 90% IN PARA 4 CHALLENGES AND THERE ARE NO DAMAGES TO DATE Rating :
(No ratings) the_p_compa...

24/Male



--------------------------------------------------------------------------------

View Messages

Report Abuse


Re: par will release zegerid 11-Mar-10 08:23 am P, Santoras now legally OWNS the formula to Zigered until a specified date in the future.

Par, on the other hand, is trying to benefit financially, and I think unethically, on the long hard efforts of others.

I still think that Santorus is in a position of strength in the litigation, and in the end will prevail, leaving those who shorted this stock on the short end of the stick!!

Good luck P. Rating :
(No ratings)Rate it: deck8magda@...

80/Male
Bedford, Te...


--------------------------------------------------------------------------------

View Messages

Ignore User

Report Abuse


Re: par will release zegerid 11-Mar-10 08:36 am the patent is invalid and unenforceable. the court has yet to rule on the 2 issues. par wants to make the powder and capsules affordable . the days for price gouging are coming to an end.par has a 90% success rate in these para 4 patent challenges, an outstanding success rate to say the least. generics are the way to go as health care is too costly. WHY SNTS HAS NOT SETTLED THIS IS BEYOND ME. when PAR RELEASES ZEGERID, IT WILL BE DEVASTATING TO QUOTE ZAKS


good luck to you and to snts in all other matters outside their undue delays and blunders with respect to the speedy release of the generic ie zegerid Rating :
(No ratings) the_p_compa...

24/Male



--------------------------------------------------------------------------------

View Messages

Report Abuse


Re: par will release zegerid 11-Mar-10 08:45 am FAR below is the reprint from zaks

until par releases zegerid, there are no damages so forget any large settlement. i expect in the next week or two par releases zegerid in 2011 and snts drops their frivilous lawsuit. IF PAR RELEASES THE POWDER AND CAPSULES NOW, IT WOULD BE DEVASTATING





zaks on par 9-Mar-10 07:13 pm However, the active patent challenge from Par Pharmaceuticals (NYSE: PRX - News) on Zegerid looms large. An unfavorable court ruling in the patent infringement case would be devastating as Santarus depends on Zegerid for growth. Rating :
(No ratings) the_p_compa...

24/Male



--------------------------------------------------------------------------------

View Messages

Report Abuse


Re: par will release zegerid 11-Mar-10 08:58 am Where was yesterday's DEVASTATING SP drop?

Speaking of drop, you'll be dropped on the ignore list. Rating :
(No ratings)Rate it: bolio98

Male



--------------------------------------------------------------------------------

View Messages

Ignore User

Report Abuse


Re: par will release zegerid 11-Mar-10 09:34 am For God's sake, quit trying to make this a moral issue. This is a legal precedent that Pharma companies have the temporary exclusive right to market a drug formula that they have spent years and financial capital developing. This precedent is not only logial but necessary for the survival of the drug industry.

Zaks is a financial "rag" that must pump out financial drivel to be gobbled up by the uniformed.

If I were you, I would'nt short the farm on their predictions. Rating :
(No ratings)Rate it: deck8magda@...

80/Male
Bedford, Te...


--------------------------------------------------------------------------------

View Messages

Ignore User

Report Abuse


Re: par will release zegerid/P's one mistake 46 minutes ago "the patent is invalid and unenforceable."

You forgot to mention or you didn't know, that Santarus was granted 2 patents for Zegarid, the first one and a second one later. This is important because PAR is alleging in their challenge to the patent that Santarus somehow mishandled the patent application. However when you consider they were given two patents at different times and upgraded the 1st one it makes it harder to believe that the Patent office would overlook obvious flaws in Santarus' application 2 times in a row. Rating :
(No ratings)Rate it: jusfercash

53/Male



--------------------------------------------------------------------------------

View Messages

Ignore User

Report Abuse


Re: par will release zegerid/P's one mistake 20 minutes ago the upgrade you allude to is tacit admission the filing was flawed


snts has a weak case, is stalling and their best outcome is to settle and hope they can delay par until 2011

snst earned a fair profit already and what judge in such circumstances will allow the higher priced branded capsule and powder compound monopoly powers when prx has every right to proceed after 30 months expired and snts failed to prove their case


sorry but zaks is right

"devastating" Rating :
(No ratings) the_p_compa...

24/Male



--------------------------------------------------------------------------------

View Messages

Report Abuse


Re: par will release zegerid/P's one mistake 3 second(s) ago and remember par bats 90% and they are quite proud of their para 4 patent challenge success rate

and weigh devastation vs no damages yet

they young ceo is quite the riverboat gambler with others monies Rating :
(No ratings)
 

Re: zaks on par 2 minutes ago


par trades slightly above book value most of which is cash and with a PE under 10

par is poorly covered by WS and is unknown like snts

par has a market cap of 800m and did over 1b in sales in 2009

par is on track for fda approval in april of a branded agent that will add over a buck or more in earnings and a second candidate later in 2010

zeg lawsuit is a blib to PRX but critically important to your beloved sn

2 points on that devastating upcoming event

since prx has yet to release the generic, snts is basically fighting to keep it off market with virtually no chance of any large financial gain, if any

and two prx bats 90% and the judge was highly critical of snts and urged sn to settle as your new ceo admits

in sum prx is a superior inv vs teva wpi bvf snts et al
 
congrats

Drug Details


Drug Name(s) AMLODIPINE; VALSARTAN (Generic Drug)
FDA Application No. (ANDA) 090011
Active Ingredient(s) AMLODIPINE; VALSARTAN
Company PAR PHARM
Original Approval or Tentative Approval Date March 19, 2010
 
.Par Pharmaceutical Companies Inc. (PRX): Zacks Rank Buy

Tracey Ryniec, On Friday April 9, 2010, 1:00 am EDT
Par Pharmaceutical Companies Inc. (NYSE: PRX - News) has surprised on the Zacks Consensus Estimate 4 quarters in a row by an average of 47%. PRX is trading with a forward P/E of only 12.6.

Company Description

Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States.

It has two divisions, Par Pharmaceutical, its generic drug segment, and Strativa Pharmaceuticals, its proprietary products segment which launched in 2005.

It currently markets and/or licenses more than 85 prescription drug products and has more than 30 products in active development.

Par Surprised in the Fourth Quarter by 14%

On Feb 24, Par Pharmaceutical reported fourth quarter results which beat the Zacks consensus by 8 cents. Earnings per share were 65 cents compared to the Zacks Consensus of 57 cents. This is also higher than the fourth quarter of 2008, where the company reported 21 cents.

Revenue rose 80% to $290.3 million from $161.3 million in the fourth quarter of 2008. For the full year, revenue jumped to $1.193 billion from $578 million in 2008.

The revenue gain was attributed to limited competition in metoprolol succinate, sumatriptan succinate, meclizine, and dronabinol.

Additionally, the launch of nateglinide and clonidine in the third quarter, and tramadol ER in the fourth quarter 2009, boosted quarterly revenue.

Tramadol ER was launched in Nov 2009 in 100mg and 200mg strengths. It is the generic version of Ortho-McNeil's Ultrama ER product of which annual U.S. sales are approximately $150 million.

Par has about 27 ANDAs pending with the FDA with 12 first-to-file opportunities with brand value of approximately $6.3 billion.

Zacks Consensus Estimates Climb

Analysts liked what they heard in February.

Estimates have been slowly rising. The first quarter Zacks Consensus is up 2 cents to 65 cents in the last 30 days.

The 2010 Zacks Consensus has increased by 4 cents to $2.01 per share. This is up sharply from just 90 days ago when analysts expected $1.64 per share.

The company reports first quarter results on May 1.

Value Fundamentals

Par Pharmaceutical is a Zacks #1 Rank (strong buy) stock. It has a price-to-book ratio of 1.8 which is under the industry average o 2.0 and within the value parameter of under 3.0.

The company also has a solid 1-year return on equity (ROE) of 18.9%.

Tracey Ryniec is the Value Stock Strategist for Zacks.com. She is also the Editor in charge of the market-beating Zacks Value Trader service.


PAR PHARMA COS (PRX): Free Stock Analysis Report
 
Par wont launch this product for 12-18months. PAr is a small generic company as well with no sales force and no thoughts of having a sales force to sell a generic drug (no need, sells itself)

SNTS will settle and keep oustanding reps.
 
Par will launch in weeks for sure

They did $1b yes billion in sales in 2009 and unlike snts were profitable

Par has a large sales force many times the size of snts

Layoffs so sorry to say are coming at snts to preserve the small cash position


Are you always so poorly informed?
 
Anonymous said:
Par wont launch this product for 12-18months. PAr is a small generic company as well with no sales force and no thoughts of having a sales force to sell a generic drug (no need, sells itself)

SNTS will settle and keep oustanding reps.
Click to expand...



This is a fine example of the intelligence of the people at snts. Par is not a "small" generic company. Par did over $1B in sales last year. Par in fact has a legitimate large sales force. Par has a tentative approval from the FDA already for all forms of Zeg. Expect a generic launch VERY soon.
 
Anonymous said:
This is a fine example of the intelligence of the people at snts. Par is not a "small" generic company. Par did over $1B in sales last year. Par in fact has a legitimate large sales force. Par has a tentative approval from the FDA already for all forms of Zeg. Expect a generic launch VERY soon.
Click to expand...


Yes indeed tentative approval already with final approval a formality this week
 
sold snts bought Par Pharma


H O P E in P R X
 
Anonymous said:
rumors of a settlement with par which could save jobs and reduce severe cuts


let's hope management does not blow it once again
Click to expand...

Why would Par settle? They won the patent law suit. They already have a tentative approval in all forms of Zeg. What could Snt offer them? Par can launch as soon as the FDA gives final approval. A settlement makes no sense for Par.
 


Write your reply...
Top Bottom
Back
Quote